EQRx No Longer Seeks To Disrupt Prices In Non-Small Cell Lung Cancer Space
The biotechnology company EQRx no longer seeks to disrupt prices in the non-small cell lung cancer space. This is disappointing news for those who had hoped for lower prices in a therapeutic category that, for the most part, has been sorely lacking real price competition for years.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals